Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.

Experimental hematology - 1 Oct 2009

Hussein Kais, Bock Oliver, Theophile Katharina, von Neuhoff Nils, Buhr Thomas, Schlué Jerome, Büsche Guntram, Kreipe Hans

Abstract excerpt

OBJECTIVE: Among Philadelphia chromosome-negative myeloproliferative neoplasms (Ph(-) MPN), essential thrombocythemia (ET) and the prefibrotic phase of primary myelofibrosis (PMF) represent two subtypes with considerable overlap. MATERIALS AND METHODS: In this study, histopathological classification of 490 MPN cases was correlated with the allelic burden of JAK2(V617F) and MPL(W515L). RESULTS: Ph(-) MPN entities...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Diagnosis, Differential

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrosis

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Share to Thrombocythemia, Essential

Source

Identifiers

PMID: 19616600
DOI: 10.1016/j.exphem.2009.07.005

Genes

JAK2
MPL

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.PMID 19616600Read ↗

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.Semantic proximity Read ↗

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read ↗

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Semantic proximity Read ↗

Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.Semantic proximity Read ↗

Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study.Semantic proximity Read ↗

Molecular and genetic bases of myeloproliferative disorders: questions and perspectives.Semantic proximity Read ↗

Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.Semantic proximity Read ↗

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis.Semantic proximity Read ↗

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.